Pharmaceutical Investing AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
Pharmaceutical Investing AbbVie Submits Biologics License Application to U.S. FDA for Pivekimab sunirine - an Investigational Antibody-Drug Conjugate to Treat Rare Cancer with Limited Treatment Options
Pharmaceutical Investing AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
Pharmaceutical Investing AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
Pharmaceutical Investing QULIPTA® Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published
Pharmaceutical Investing Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
Pharmaceutical Investing Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
Pharmaceutical Investing BOTOX® Cosmetic Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
Pharmaceutical Investing AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pharmaceutical Investing Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid Injectable Fillers
Standard Uranium Announces Expansion of Davidson River Drill Program and Provides Update on Private Placement and LIFE Offering
